Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Beacon Therapeutics logo — Transforming Vision, Transforming Lives

Beacon Therapeutics

Transforming Vision, Transforming Lives

Founded 2023 United Kingdom London, United Kingdom 95 employees Series C Total: $341.00M Biotechnology, Health Care +1

General Information

Company Name Beacon Therapeutics
Founded Year 2023
Location United Kingdom London, United Kingdom +2
Employees 95
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

Get notified when Beacon Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Beacon Therapeutics

Beacon Therapeutics is a United States based ophthalmic gene therapy company that aims to restore and enhance the sight of patients suffering from a variety of prevalent and rare retinal diseases leading to blindness. The company's scientific foundation encompasses a late-stage development candidate for treating X-linked retinitis pigmentosa (XLRP), along with two preclinical programs targeting dry age-related macular degeneration (AMD) and cone-rod dystrophy (CRD), an inherited retinal disease from the University of Oxford. The lead development candidate, AGTC-501, is a gene therapy program currently in Phase II clinical trials to treat XLRP, a disorder causing progressive vision loss primarily in boys and young men. The company's access to a target generation technology platform for identifying, screening, and researching secreted proteins in the ophthalmology space bolsters its offerings. Beacon Therapeutics is financially backed by funds from Syncona and other investors, including Oxford Science Enterprises. The company secured a £96.00M Series A investment on 12 June 2023. For more information, visit their website at www.beacontx.com.

Taxonomy: ophthalmic gene therapy, retinal diseases, X-linked retinitis pigmentosa, AMD (age-related macular degeneration), Cone-rod dystrophy, gene therapy program, RPGR gene, clinical trials, target generation technology, Syncona, Oxford Science Enterprises, inherited retinal diseases, vision restoration, blindness

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 6
Investor Investor Investor Investor Investor Investor
01 Jan 2026
Series B •••••• 5
Investor Investor Investor Investor
•••• •••• 		01 Jul 2024
Series A •••••• 2
Investor Investor
01 Jun 2023
Spinout •••••• 1
Investor
01 Jan 2023

Beacon Therapeutics Alternatives & Competitors

Beacon Therapeutics vs
VIAN Therapeutics
VIAN Therapeutics United States

Protecting sight with a simple eye drop.

Seed
4 employees
Biotechnology, Pharmaceutical
Compare Beacon Therapeutics vs VIAN Therapeutics
Beacon Therapeutics vs
Complement Therapeutics
Complement Therapeutics Germany

Developing the next generation of complement medicines

Series A
36 employees
Biotechnology
Compare Beacon Therapeutics vs Complement Therapeutics
Beacon Therapeutics vs
Opus Genetics
Opus Genetics United States

Gene therapy company for inherited retinal diseases

Grant
42 employees
Health Care, Health and Wellness
Compare Beacon Therapeutics vs Opus Genetics
Also compare with: Beacon Therapeutics vs GenSight Biologics GenSight Biologics Beacon Therapeutics vs Ray Therapeutics, Inc. Ray Therapeutics, Inc.

FAQ About Beacon Therapeutics

Transforming Vision, Transforming Lives
Beacon Therapeutics was founded in 2023.
Beacon Therapeutics is headquartered in London, United Kingdom.
Beacon Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Beacon Therapeutics has approximately 95 employees.
Beacon Therapeutics has completed 4 funding rounds, raising a total of $341.00M. The latest funding stage is Series C.
Top alternatives and competitors to Beacon Therapeutics include VIAN Therapeutics, Complement Therapeutics, Opus Genetics, GenSight Biologics, Epigenic Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Beacon Therapeutics and VIAN Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Beacon Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy